Tandem Diabetes Care (TNDM) Net Cash Flow Growth (1y) (2014 - 2026)
Tandem Diabetes Care (TNDM) Net Cash Flow Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.52 Bn | 176.22 Bn | 6.27 Bn | -53.07% |
| 2 | Stryker | 128.83 Bn | 125.95 Bn | 3.81 Bn | 17.60% |
| 3 | Medtronic | 108.61 Bn | 99.39 Bn | 6.41 Bn | 10.50% |
| 4 | Boston Scientific | 68.35 Bn | 66.90 Bn | 3.61 Bn | -283.58% |
| 5 | Edwards Lifesciences | 48.53 Bn | 44.86 Bn | 1.29 Bn | -564.44% |
| 6 | Dexcom | 28.42 Bn | 27.30 Bn | 750.30 Mn | -31.84% |
| 7 | GE HealthCare Technologies | 28.34 Bn | 26.06 Bn | 1.98 Bn | -394.13% |
| 8 | Smith & Nephew | 26.92 Bn | 26.35 Bn | - | - |
| 9 | Koninklijke Philips | 25.49 Bn | 22.36 Bn | 2.07 Bn | 76.43% |
| 10 | Tandem Diabetes Care | 1.14 Bn | 574.03 Mn | 136.79 Mn | 751.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 751.43% |
| Dec 31, 2025 | -114.33% |
| Sep 30, 2025 | 1,051.86% |
| Jun 30, 2025 | 175.49% |
| Mar 31, 2025 | -2,680.52% |
| Dec 31, 2024 | 185.11% |
| Sep 30, 2024 | 104.69% |
| Jun 30, 2024 | -455.61% |
| Mar 31, 2024 | 101.18% |
| Dec 31, 2023 | -144.41% |
| Sep 30, 2023 | -659.42% |
| Jun 30, 2023 | -84.41% |
| Mar 31, 2023 | -300.90% |
| Dec 31, 2022 | 215.50% |
| Sep 30, 2022 | -34.70% |
| Jun 30, 2022 | 195.80% |
| Mar 31, 2022 | -14.02% |
| Dec 31, 2021 | -17.37% |
| Sep 30, 2021 | 114.78% |
| Jun 30, 2021 | -115.05% |